Skip to content

Our science

Explore the Research Behind Femarelle

Discover what researchers have studied about DT56a — from everyday menopause experiences to bone health and tissue-selective biology.

What is DT56a?

DT56a is a proprietary compound derived from soy and the signature ingredient across the Femarelle range. It is hormone-free.

Researchers describe DT56a as having selective, tissue-dependent activity: rather than acting the same way everywhere, it has shown different biological responses in different tissues, such as bone and the uterus. Scientists call this kind of profile "selective estrogen receptor modulation."

User-provided gold circular artwork reading “Recommended by the European Society of Gynecology” and “Position Statement Nov. 2026”; endorsement wording pending approval.

European Science · November 2026

DT56a in the European Society of Gynecology’s 2026 Position Statement

The European Society of Gynecology’s statement on non-hormonal menopause management includes DT56a in its discussion of complementary approaches.

Hot Flashes

Clinical study • 631 women

80.7% Reported Improvement in Hot Flashes

Researchers followed peri- and postmenopausal women in Spain who used DT56a during everyday care.

In a four-week study involving 631 women in Spain, 80.7% described their hot flashes as better or much better.

Study details

Prospective observational study (Sánchez-Borrego et al., Climacteric, 2015). Participants documented hot-flash experiences in daily diaries over four weeks.

Open on PubMed

Clinical study • 260 women

Hot-Flash Frequency and Severity Improved Over Eight Weeks

A multicenter study in Taiwan followed postmenopausal women using Femarelle for eight weeks.

The study reported improvements in hot-flash frequency and severity, along with overall climacteric symptom scores.

Study details

Multicenter open-label trial with 260 postmenopausal women (Taiwanese Journal of Obstetrics & Gynecology, 2016).

Open on PubMed

Bone Health

Clinical study • postmenopausal women

3.6% Increase in Lumbar Spine Bone Density

Researchers measured bone mineral density with DXA scans in postmenopausal women over 12 months.

In a 12-month study of postmenopausal women, the higher-dose DT56a group showed a 3.6% rise in lumbar spine bone mineral density.

Study details

A 12-month comparison of two DT56a dose regimens in postmenopausal women (Menopause, 2003); 98 women enrolled, 82 with 12-month measurements. Bone mineral density was measured using DXA scans.

Open on PubMed

Human cell research

DT56a Stimulated Markers of Bone-Forming Cell Activity

Laboratory scientists studied human-derived osteoblasts, the cells that build bone, grown in culture.

Laboratory research using human-derived osteoblasts observed changes in markers related to bone-cell activity.

Study details

In-vitro laboratory experiment using cultured human-derived osteoblasts (Somjen et al., Journal of Steroid Biochemistry & Molecular Biology, 2006).

Open on PubMed

Vaginal Wellness

Clinical study • 12 women

Research Explores Vaginal Health and Comfort

Researchers measured vaginal tissue markers, pH and quality of life in postmenopausal women over 12 weeks.

In a published 2026 study, 11 of 12 participants showed improvements in vaginal maturation measures and quality-of-life scores after 12 weeks.

Study details

Open-label study in postmenopausal women with vulvovaginal atrophy (Gynecological Endocrinology, published online 6 September 2026). An earlier 2011 NAMS conference abstract describes related work and is listed here as a related abstract.

Related abstract: A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal Vaginal Atrophy (NAMS Annual Congress presentation abstract, 2011)

Open on PubMed

Menopausal Well-being

Clinical study • 89 women

Menopausal Symptom Scores Improved in a Comparative Study

Researchers followed women using DT56a, women using hormone therapy, and women using neither for 12 months.

A 12-month study of 89 postmenopausal women evaluated DT56a alongside hormone therapy and an untreated comparison group; menopausal symptom scores improved in the DT56a group.

Study details

Comparative 12-month study in Greece involving 27 women using DT56a, 26 using hormone therapy, and 36 in an untreated comparison group (Journal of Endocrinological Investigation, 2013).

Open on PubMed

Clinical study • 453 women

Women Reported Better Sleep and Fewer Hot Flashes

A four-week study in Slovakia and the Czech Republic followed women with menopausal symptoms.

85% experienced lower hot-flash frequency or intensity, 65% reported better sleep, and muscle and joint aches decreased in the study.

Study details

Prospective open-label study with 453 women (Bratislavské lekárske listy, 2021).

Open on PubMed

Tissue Selectivity

Preclinical research

DT56a Showed Tissue-Selective Biological Activity

Scientists compared how skeletal, vascular and uterine tissues responded to DT56a in laboratory and animal models.

Preclinical research found different biological responses in skeletal and uterine tissue, advancing understanding of DT56a's proposed SERM-like mechanism.

Study details

Rat tissue models and cultured human cells (Journal of Steroid Biochemistry & Molecular Biology, 2003 and 2007). These studies explored the mechanism of DT56a of action at the tissue and cellular level.

Open on PubMed
Open on PubMed

More Research

Clinical study • 32 women

Measured Platelet Reactivity Remained Unchanged

Researchers measured a laboratory marker of platelet function in postmenopausal women using DT56a.

Measured platelet closure time did not change significantly during the study.

Study details

Human study of 32 women, including seven with thrombophilia (Menopause, 2011). Platelet function was measured by laboratory testing.

Open on PubMed

Laboratory experiment

No Proliferation Observed in Tested MCF-7 Cells

Scientists exposed one estrogen-sensitive breast-cancer cell line to DT56a in the laboratory.

At the tested concentrations, DT56a did not stimulate proliferation of the MCF-7 cells.

Study details

Cell-culture letter (European Journal of Obstetrics & Gynecology and Reproductive Biology, 2007). The experiment measured cell proliferation in a laboratory cell line.

Open on PubMed

Animal research • rats

Neurosteroid Changes Observed in Preclinical Brain Research

Researchers examined brain signaling molecules in a rat model of estrogen decline.

DT56a changed measured allopregnanolone and beta-endorphin content in selected brain regions.

Study details

Study in a rat model focused on brain signaling molecules (Menopause, 2009).

Open on PubMed
Publication Library22 publications with journal, year and study type

If a new tab is blocked, copy the study link and paste it into your browser.

Femarelle research collection (17)

  • Clinical study · 2015

    A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms

    Climacteric

    Researchers followed women experiencing hot flashes during everyday care and tracked their experiences.

    Open on PubMed
  • Clinical study · 2004

    Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms

    Clinical and Experimental Obstetrics & Gynecology

    The study compared two amounts of DT56a in postmenopausal women over 12 months.

    Open on PubMed
  • Clinical study · 2003

    Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss

    Menopause

    This study measured bone density by DXA scans in postmenopausal women.

    Open on PubMed
  • Clinical study · 2013

    Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women

    Journal of Endocrinological Investigation

    Researchers compared symptom changes for women using DT56a, hormone therapy, or neither.

    Open on PubMed
  • Clinical study · 2011

    The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women

    Menopause

    The study asked whether a laboratory measure of platelet function changed while women used DT56a.

    Open on PubMed
  • Conference abstract · 2011

    A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal Vaginal Atrophy

    NAMS Annual Congress presentation abstract

    An early report examining intimate-health symptoms and vaginal tissue measures.

    Conference abstract · citation only
  • Laboratory research · 2007

    Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line

    European Journal of Obstetrics & Gynecology and Reproductive Biology (letter)

    Researchers examined how one estrogen-sensitive type of breast-cancer cell responded in a laboratory dish.

    Open on PubMed
  • Animal research · 2011

    The effects of native and synthetic estrogenic compounds as well as vitamin D less-calcemic analogs on adipocytes content in rat bone marrow

    Journal of Endocrinological Investigation

    The study explored biological changes in bone marrow after an experimentally induced estrogen decline.

    Open on PubMed
  • Animal research · 2003

    DT56a stimulates creatine kinase specific activity in vascular tissues of rats

    Journal of Endocrinological Investigation

    Researchers tested tissue-selective biological activity in blood-vessel and heart tissue.

    Open on PubMed
  • Animal research · 2003

    DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus

    Journal of Steroid Biochemistry & Molecular Biology

    This experiment informed the proposed tissue-selective mechanism.

    Open on PubMed
  • Laboratory research · 2006

    DT56a stimulates gender-specific human cultured bone cells in vitro

    Journal of Steroid Biochemistry & Molecular Biology

    Osteoblasts are cells involved in building bone; this helps explore possible mechanisms.

    Open on PubMed
  • Laboratory research · 2017

    Interaction between the effects of the selective estrogen modulator femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells

    Journal of Steroid Biochemistry & Molecular Biology

    Mechanistic laboratory research on vascular cell behavior.

    Open on PubMed
  • Laboratory research · 2011

    DT56a (Femarelle), contrary to estradiol-17β, is effective in human derived female osteoblasts in hyperglycemic condition

    Journal of Steroid Biochemistry & Molecular Biology

    The lab explored bone-cell responses under an artificial high-glucose environment.

    Open on PubMed
  • Animal research · 2009

    Brain-region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats

    Menopause

    The study investigated biological pathways associated with stress, mood and brain signaling.

    Open on PubMed
  • Animal research · 2005

    Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract

    Reproductive Toxicology

    This research assessed aspects of reproductive-tissue response in animals.

    Open on PubMed
  • Preclinical research · 2007

    DT56a (Femarelle): A natural selective estrogen receptor modulator (SERM)

    Journal of Steroid Biochemistry & Molecular Biology

    This study explores what 'selective' means at the cellular and tissue level.

    Open on PubMed
  • Animal research · 2005

    DT56a (Femarelle) stimulates bone formation in female rats

    BJOG

    Research tested bone architecture directly in an animal model of estrogen deficiency.

    Open on PubMed

Additional public studies (5)

Further publications indexed on PubMed.

  • Clinical study · 2016

    Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial

    Taiwanese Journal of Obstetrics & Gynecology

    Women recorded changes in menopausal symptoms during an eight-week open-label study.

    Open on PubMed
  • Clinical study · 2021

    DT56a in treatment of climacteric syndrome in the Central European population sample

    Bratislavské lekárske listy

    A four-week European study considered daily menopausal symptoms, sleep and joint/muscle concerns.

    Open on PubMed
  • Clinical study · 2026

    DT56a (Femarelle) effectively manages vulvovaginal atrophy in postmenopausal women

    Gynecological Endocrinology (online 6 September 2026)

    Researchers measured vaginal tissue markers, pH and symptoms in postmenopausal women over three months.

    Open on PubMed
  • Clinical study · 2026

    Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome

    Gynecologic and Obstetric Investigation (online 22 June 2026)

    This comparison looked at systemic menopause symptoms as well as urinary and sexual-health measures.

    Open on PubMed
  • Research review · 2015

    Efficacy and safety of a phyto-SERM as an alternative to hormone therapy

    Climacteric (review)

    A review can help readers understand the broader research and its open questions.

    Open on PubMed